The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

S&P 500 pharma stocks hold firm despite Trump’s drug pricing threat. Is Merck a put-selling opportunity amid headline noise?

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

On the heels of President Donald Trump’s Monday announcement of an executive order that will slash prescription drug prices ...

The order calls on the health department, led by Robert F. Kennedy Jr., to broker new price tags for drugs over the next ...

Robert F. Kennedy Jr. cited Bernie Sanders' 2016 and 2020 White House campaign plans on prescription drugs to highlight Trump's efforts in 2025.